HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation.

Abstract
The cancer mortality rate of hepatocellular carcinoma (HCC) is the second highest in the world and the therapeutic options are limited. The incidence of this deadly cancer is rising at an alarming rate because of the high degree of resistance to chemo- and radiotherapy, lack of proper, and adequate vaccination to hepatitis B, and lack of consciousness and knowledge about the disease itself and the lifestyle of the people. DNA methylation and DNA methylation-induced epigenetic alterations, due to their potential reversibility, open the access to develop novel biomarkers and therapeutics for HCC. The contribution to these epigenetic changes in HCC development still has not been thoroughly summarized. Thus, it is necessary to better understand the new molecular targets of HCC epigenetics in HCC diagnosis, prevention, and treatment. This review elaborates on recent key findings regarding molecular biomarkers for HCC early diagnosis, prognosis, and treatment. Currently emerging epigenetic drugs for the treatment of HCC are summarized. In addition, combining epigenetic drugs with nonepigenetic drugs for HCC treatment is also mentioned. The molecular mechanisms of DNA methylation-mediated HCC resistance are reviewed, providing some insights into the difficulty of treating liver cancer and anticancer drug development.
AuthorsAimei Liu, Qinghua Wu, Dapeng Peng, Irma Ares, Arturo Anadón, Bernardo Lopez-Torres, María-Rosa Martínez-Larrañaga, Xu Wang, María-Aránzazu Martínez
JournalMedicinal research reviews (Med Res Rev) Vol. 40 Issue 5 Pg. 1973-2018 (09 2020) ISSN: 1098-1128 [Electronic] United States
PMID32525219 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright© 2020 Wiley Periodicals LLC.
Topics
  • Carcinoma, Hepatocellular (diagnosis, drug therapy, genetics)
  • DNA Methylation
  • Drug Resistance, Neoplasm
  • Humans
  • Liver Neoplasms (diagnosis, drug therapy, genetics)
  • Prognosis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: